BridgeBio: 3 Key Takeaways for Long-Term Investors

Source Motley_fool

Key Points

  • Attruby net product revenue grew 134% year over year to $253.2 million.

  • BBP-418 faces a Nov. 27 target action date for full approval.

  • The company holds $1.5 billion in cash and marketable securities.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Oct. 29, 2026, BridgeBio (NASDAQ:BBIO) announced net product revenue of $253.2 million for Attruby, up 134% year over year. Commercial momentum across rare disease therapies expands the company's addressable market beyond $8 billion in peak annual sales.

Three things management said stand out.

1. Real-World Evidence Drives First-Line Growth for Attruby

Growth for Attruby, a treatment for transthyretin amyloid cardiomyopathy (a heart condition caused by misfolded proteins), stems from new patients starting therapy first rather than switching. Comparative real-world data showing reduced hospitalizations reinforce management's long-term sales projections.

Attruby U.S. net product revenue was $253.2 million, an increase of approximately 14% quarter-on-quarter and approximately 134% year-over-year.
-- Neil Kumar, Chief Executive Officer

2. Imminent Action Date Positions BBP-418 for Near-Term Launch

The company expects a Food and Drug Administration decision by its Nov. 27, 2026, target action date under the Prescription Drug User Fee Act for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I (a genetic muscle disease). Management has identified over 500 patients in the U.S.

Given their continued engagement and feedback to date, we're confident that this will be a traditional full approval and everything is looking on track for the November 27 PDUFA action date.
-- Anna Wade, Leader of Neuromuscular Franchise

3. Priority Reviews Accelerate Two Additional Rare Disease Launches

Priority reviews by regulatory authorities set early target action dates for infigratinib in achondroplasia (a genetic bone growth disorder) and encaleret in autosomal dominant hypocalcemia type 1 (a rare hormone disorder). These approvals would expand the company's commercial rare disease portfolio in 2027.

On October 6, the FDA accepted our NDA with priority review and set a PDUFA date of February 4, 2027, ahead of the mid-2027 launch timing we described last quarter.
-- Matthew Outten, Chief Commercial Officer

Looking Ahead

Three commercial launches arrive within seven months, marking an operational shift. Management relies on field teams and digital tools to broaden prescriber coverage while expanding margins toward corporate breakeven.

As we look forward to next year, I see a continued margin expansion from Attruby improving operating line throughout the course of the year toward a breakeven point.
-- Thomas Trimarchi, President and Chief Financial Officer

A balance sheet holding $1.5 billion supports these launches while funding late-stage clinical development.

So put simply, we are a company with 3 launches in the next 7 months. I'm not aware of many companies our size that have been handed that type of opportunity, and we don't intend to waste it.
-- Neil Kumar, Chief Executive Officer

Should you buy stock in BridgeBio Pharma right now?

Before you buy stock in BridgeBio Pharma, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BridgeBio Pharma wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*

Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 22, 2026.

The Motley Fool recommends BridgeBio Pharma. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Today: Can XAU/USD Hold $3,500? | Mitrade AUGold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
Author  Mitrade Team
Nov 20, Fri
Gold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
placeholder
Australia’s jobs market just cracked — has the AUD/USD rate story flipped?Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
Author  Mark Garro
Nov 20, Fri
Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
placeholder
Market News Today Australia: VIX Surges Nearly 16%, Gold Breaks US$3,600 and US Stocks SlideVIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
Author  Mitrade Team
Nov 20, Fri
VIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
placeholder
Is Tech in a Bear Market? 20 Tech Stocks Fall Up to 76% From HighsAll 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
Author  Beincrypto
Nov 20, Fri
All 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
placeholder
Gold and Bitcoin Are Falling. Peter Schiff Sees Opportunities for BothPeter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
Author  Beincrypto
Nov 20, Fri
Peter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
goTop
quote